{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:54:39Z","timestamp":1760608479990},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,12,14]],"date-time":"2007-12-14T00:00:00Z","timestamp":1197590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s11064-007-9526-3","type":"journal-article","created":{"date-parts":[[2007,12,13]],"date-time":"2007-12-13T22:03:47Z","timestamp":1197583427000},"page":"861-866","source":"Crossref","is-referenced-by-count":32,"title":["Chronic Administration of Lamotrigine Downregulates COX-2 mRNA and Protein in Rat Frontal Cortex"],"prefix":"10.1007","volume":"33","author":[{"given":"Ho-Joo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee N.","family":"Ertley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley I.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Bazinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadeesh S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,14]]},"reference":[{"key":"9526_CR1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","volume":"60","author":"JR Calabrese","year":"1999","unstructured":"Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79\u201388","journal-title":"J Clin Psychiatry"},{"key":"9526_CR2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.eurpsy.2004.12.003","volume":"20","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Findling RL (2005) New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry 20:92\u201395","journal-title":"Eur Psychiatry"},{"key":"9526_CR3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(00)00196-0","volume":"43","author":"B Hassel","year":"2001","unstructured":"Hassel B, Tauboll E, Gjerstad L (2001) Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res 43:153\u2013163","journal-title":"Epilepsy Res"},{"key":"9526_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.bjp.0705737","volume":"142","author":"S Ahmad","year":"2004","unstructured":"Ahmad S, Fowler LJ, Whitton PS (2004) Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 142:136\u2013142","journal-title":"Br J Pharmacol"},{"key":"9526_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00210-004-1008-4","volume":"371","author":"S Ahmad","year":"2005","unstructured":"Ahmad S, Fowler LJ, Whitton PS (2005) Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 371:1\u20138","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"9526_CR6","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1016\/S0021-9258(19)39374-3","volume":"265","author":"JY Channon","year":"1990","unstructured":"Channon JY, Leslie CC (1990) A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. J Biol Chem 265:5409\u20135413","journal-title":"J Biol Chem"},{"key":"9526_CR7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1073\/pnas.93.6.2317","volume":"93","author":"WE Kaufmann","year":"1996","unstructured":"Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317\u20132321","journal-title":"Proc Natl Acad Sci USA"},{"key":"9526_CR8","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1074\/jbc.273.23.14411","volume":"273","author":"M Murakami","year":"1998","unstructured":"Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfield JA, Kudo I (1998) The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem 273:14411\u201314423","journal-title":"J Biol Chem"},{"key":"9526_CR9","first-page":"3","volume-title":"Enzymes of membrane phospholipid metabolism","author":"WEM Lands","year":"1976","unstructured":"Lands WEM, Crawford CG (1976) Enzymes of membrane phospholipid metabolism. Plenum, New York, pp 3\u201385"},{"key":"9526_CR10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3171\/jns.1985.63.5.0659","volume":"63","author":"JB Leslie","year":"1985","unstructured":"Leslie JB, Watkins WD (1985) Eicosanoids in the central nervous system. J Neurosurg 63:659\u2013668","journal-title":"J Neurosurg"},{"key":"9526_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1615\/CritRevNeurobiol.v13.i1.30","volume":"13","author":"MK O\u2019Banion","year":"1999","unstructured":"O\u2019Banion MK (1999) Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 13:45\u201382","journal-title":"Crit Rev Neurobiol"},{"key":"9526_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.biopsych.2005.07.024","volume":"59","author":"RP Bazinet","year":"2006","unstructured":"Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee HJ (2006) Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 59:401\u2013407","journal-title":"Biol Psychiatry"},{"key":"9526_CR13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1471-4159.2001.00311.x","volume":"77","author":"MC Chang","year":"2001","unstructured":"Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI (2001) Chronic valproate treatment decreases the in\u00a0vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 77:796\u2013803","journal-title":"J Neurochem"},{"key":"9526_CR14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0304-3940(96)13264-X","volume":"220","author":"MC Chang","year":"1996","unstructured":"Chang MC, Grange E, Rabin O, Bell JM, Allen DD, Rapoport SI (1996) Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 220:171\u2013174","journal-title":"Neurosci Lett"},{"key":"9526_CR15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biopsych.2004.05.012","volume":"56","author":"S Ghelardoni","year":"2004","unstructured":"Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F (2004) Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 56:248\u2013254","journal-title":"Biol Psychiatry"},{"key":"9526_CR16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1399-5618.2007.00361.x","volume":"9","author":"JS Rao","year":"2007","unstructured":"Rao JS, Bazinet RP, Rapoport SI, Lee HJ (2007) Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord 9:513\u2013520","journal-title":"Bipolar Disord"},{"key":"9526_CR17","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1097\/00001756-199912160-00030","volume":"10","author":"J Rintala","year":"1999","unstructured":"Rintala J, Seemann R, Chandrasekaran K, Rosenberger TA, Chang L, Contreras MA, Contreras MA, Rapoport SI, Chang MC (1999) 85\u00a0kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10:3887\u20133890","journal-title":"Neuroreport"},{"key":"9526_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biopsych.2006.03.029","volume":"61","author":"JS Rao","year":"2007","unstructured":"Rao JS, Bazinet RP, Rapoport SI, Lee HJ (2007) Chronic administration of carbamazepine down-regulates AP-2 DNA-binding activity and AP-2alpha protein expression in rat frontal cortex. Biol Psychiatry 61:154\u2013161","journal-title":"Biol Psychiatry"},{"key":"9526_CR19","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.npp.1300740","volume":"30","author":"JS Rao","year":"2005","unstructured":"Rao JS, Rapoport SI, Bosetti F (2005) Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6\u00a0weeks. Neuropsychopharmacology 30:2006\u20132013","journal-title":"Neuropsychopharmacology"},{"key":"9526_CR20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.mp.4001111","volume":"7","author":"F Bosetti","year":"2002","unstructured":"Bosetti F, Rintala J, Seemann R, Rosenberger TA, Contreras MA, Rapoport SI, Chang MC (2002) Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry 7:845\u2013850","journal-title":"Mol Psychiatry"},{"key":"9526_CR21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1471-4159.2003.01701.x","volume":"85","author":"F Bosetti","year":"2003","unstructured":"Bosetti F, Weerasinghe GR, Rosenberger TA, Rapoport SI (2003) Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 85:690\u2013696","journal-title":"J Neurochem"},{"key":"9526_CR22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0006-3223(99)00316-9","volume":"47","author":"SL McElroy","year":"2000","unstructured":"McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM (2000) Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 47:1025\u20131033","journal-title":"Biol Psychiatry"},{"key":"9526_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-5618.2006.00276.x","volume":"8","author":"SF Kushner","year":"2006","unstructured":"Kushner SF, Khan A, Lane R, Olson WH (2006) Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 8:15\u201327","journal-title":"Bipolar Disord"},{"key":"9526_CR24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-2189-3","volume":"180","author":"S Ghelardoni","year":"2005","unstructured":"Ghelardoni S, Bazinet RP, Rapoport SI, Bosetti F (2005) Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl) 180:523\u2013529","journal-title":"Psychopharmacology (Berl)"},{"key":"9526_CR25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11064-005-2756-3","volume":"30","author":"HJ Lee","year":"2005","unstructured":"Lee HJ, Ghelardoni S, Chang L, Bosetti F, Rapoport SI, Bazinet RP (2005) Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat. Neurochem Res 30:677\u2013683","journal-title":"Neurochem Res"},{"key":"9526_CR26","first-page":"524","volume":"51","author":"R Feder","year":"1990","unstructured":"Feder R (1990) Fluoxetine-induced mania. J Clin Psychiatry 51:524\u2013525","journal-title":"J Clin Psychiatry"},{"key":"9526_CR27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archpsyc.60.4.392","volume":"60","author":"CL Bowden","year":"2003","unstructured":"Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392\u2013400","journal-title":"Arch Gen Psychiatry"},{"key":"9526_CR28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4088\/JCP.v58n1202","volume":"58","author":"SH Fatemi","year":"1997","unstructured":"Fatemi SH, Rapport DJ, Calabrese JR, Thuras P (1997) Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 58:522\u2013527","journal-title":"J Clin Psychiatry"},{"key":"9526_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00213-007-0803-2","volume":"193","author":"HJ Lee","year":"2007","unstructured":"Lee HJ, Rao JS, Chang L, Rapoport SI, Bazinet RP (2007) Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. Psychopharmacology (Berl) 193:467\u2013474","journal-title":"Psychopharmacology (Berl)"},{"key":"9526_CR30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.biopsych.2003.10.017","volume":"55","author":"IK Lyoo","year":"2004","unstructured":"Lyoo IK, Kim MJ, Stoll AL, Demopulos CM, Parow AM, Dager SR, Friedman SD, Dunner DL, Renshaw PF (2004) Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry 55:648\u2013651","journal-title":"Biol Psychiatry"},{"key":"9526_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1399-5618.2002.01149.x","volume":"4","author":"G Rajkowska","year":"2002","unstructured":"Rajkowska G (2002) Cell pathology in bipolar disorder. Bipolar Disord 4:105\u2013116","journal-title":"Bipolar Disord"},{"key":"9526_CR32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","volume":"44","author":"DR Doose","year":"2003","unstructured":"Doose DR, Brodie MJ, Wilson EA, Chadwick D, Oxbury J, Berry DJ, Schwabe S, Bialer M (2003) Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 44:917\u2013922","journal-title":"Epilepsia"},{"key":"9526_CR33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.tpj.6500391","volume":"6","author":"JS Rao","year":"2006","unstructured":"Rao JS, Ertley RN, Lee HJ, Rapoport SI, Bazinet RP (2006) Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J 6:413\u2013420","journal-title":"Pharmacogenomics J"},{"key":"9526_CR34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"9526_CR35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archpsyc.59.7.592","volume":"59","author":"SI Rapoport","year":"2002","unstructured":"Rapoport SI, Bosetti F (2002) Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 59:592\u2013596","journal-title":"Arch Gen Psychiatry"},{"key":"9526_CR36","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa064135","volume":"356","author":"GS Sachs","year":"2007","unstructured":"Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356:1711\u20131722","journal-title":"N Engl J Med"},{"key":"9526_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-006-0582-1","volume":"190","author":"HJ Lee","year":"2007","unstructured":"Lee HJ, Rao JS, Ertley RN, Chang L, Rapoport SI, Bazinet RP (2007) Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl) 190:103\u2013115","journal-title":"Psychopharmacology (Berl)"},{"key":"9526_CR38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","volume":"11","author":"N Muller","year":"2006","unstructured":"Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680\u2013684","journal-title":"Mol Psychiatry"},{"key":"9526_CR39","unstructured":"Soares JC, Nery FG, Monkul ES, Fonseca M, Zunta GB, Frey BN, Hatch JP (2006) A COX-2 inhibitor (celecoxib) as a possible adjunctive agent to expedite treatment response in bipolar depression. ACNP Program No 71"},{"key":"9526_CR40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000542-200502000-00026","volume":"102","author":"G Dembo","year":"2005","unstructured":"Dembo G, Park SB, Kharasch ED (2005) Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 102:409\u2013415","journal-title":"Anesthesiology"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-007-9526-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-007-9526-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-007-9526-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T15:29:26Z","timestamp":1630337366000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-007-9526-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,14]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["9526"],"URL":"https:\/\/doi.org\/10.1007\/s11064-007-9526-3","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,14]]}}}